HMOX1 and ovarian carcinoma: Similarly, co-treatment with shikonin and cisplatin has been shown to activate HMOX1 (Heme oxygenase 1) and promote iron accumulation, inducing ferroptosis and mitigating cisplatin resistance in ovarian cancer (Ni et al., 2023).